Business
Lipocine to Present Clinical Data on LPCN 1148 at The Liver Meeting® 2023
"Late Breaking" abstract scheduled for oral presentation on November 13 SALT LAKE CITY, Nov. 1, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a
About this update from Lipocine Inc.
[{"type":"text","content":"\"Late Breaking\" abstract scheduled for oral presentation on November 13\nSALT LAKE CITY, Nov. 1, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that an abstract on LPCN 1148 has been selected for a late breaking oral presentation at The American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2023, to take place in Boston MA, November 10 to 14, 2023.\n\n \n \n \n \n \n \n\n \nPresentation Details \nTitle \nOral LPCN 1148 improves sarcopenia and hepatic encephalopathy in patients with cirrhosis\nPresenter: \nDr. Arun J. Sanyal, MD, Director, Stravitz-Sanyal Institute for Liver Disease and Metabolic Health, Virginia Commonwealth University Advisor to Lipocine \nSession Title: \nLate Breaking Abstract #1\nSession Date and Time: \nMonday, November 13, 2023, 2:00 PM - 3:30 PM ET\nPresentation Time: \n2:45 PM ET\nAbstract Number: \n5003\nAbout LPCN 1148 \nLipocine is currently evaluating LPCN 1148 comprising testosterone laurate (\"TL\") for the management of decompensated cirrhosis. The Company believes LPCN 1148 targets unmet needs for patients with advanced cirrhosis including improvement in the quality of life of patients while on the liver transplant waitlist, prevention or reduction in the occurrence of new decompensation events such as hepatic encephalopathy (\"HE\"), and improvement in post liver transplant outcomes including survival and costs.\nAbout Lipocine\nLipocine is a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery to develop differentiated products for CNS disorders. Lipocine has drug candidates in development as well as drug candidates for which we are exploring partnering. Our drug candidates represent enablement of differentiated, patient friendly oral delivery options for favorable benefit to risk profile which target large addressable markets with significant unmet medical needs. \nLipocine's clinical development candidates include: LPCN 1154, oral brexanolone, for the potential treatment of postpartum depression, LPCN 2101 for the potential treatment of epilepsy and LPCN 1148, a novel androgen receptor agonist prodrug for oral administration targeted for the management of symptoms associated with liv...